Determination of ReQuest™-Based Symptom Thresholds to Define Symptom Relief in GERD Clinical Studies
- 1 March 2005
- journal article
- research article
- Published by S. Karger AG in Digestion
- Vol. 71 (3) , 145-151
Abstract
Background/Aims: The growing importance of symptom assessment is evident from the numerous clinical studies on gastroesophageal reflux disease (GERD) assessing treatment-induced symptom relief. However, to date, the a priori selection of criteria defining symptom relief has been arbitrary. The present study was designed to prospectively identify GERD symptom thresholds for the broad spectrum of GERD-related symptoms assessed by the validated reflux questionnaire (ReQuest™) and its subscales, ReQuest™-GI (gastrointestinal symptoms) and ReQuest™-WSO (general well-being, sleep disturbances, other complaints), in individuals without evidence of GERD. Methods: In this 4-day evaluation in Germany, 385 individuals without evidence of GERD were included. On the first day, participants completed the ReQuest™, the Gastrointestinal Symptom Rating Scale, and the Psychological General Well-Being scale. On the other days, participants filled in the ReQuest™ only. GERD symptom thresholds were calculated for ReQuest™ and its subscales, based on the respective 90th percentiles. Results: GERD symptom thresholds were 3.37 for ReQuest™, 0.95 for ReQuest™-GI, and 2.46 for ReQuest™-WSO. Conclusion: Even individuals without evidence of GERD may experience some mild symptoms that are commonly ascribed to GERD. GERD symptom thresholds derived in this study can be used to define the global symptom relief in patients with GERD.Keywords
This publication has 16 references indexed in Scilit:
- The Construction of a New Evaluative GERD Questionnaire – Methods and State of the ArtDigestion, 2004
- International validation of ReQuest in patients with endoscopy-negative gastro-oesophageal reflux diseaseAlimentary Pharmacology & Therapeutics, 2004
- Evaluation of GERD Symptoms during Therapy. Part IIDigestion, 2004
- Evaluation of GERD Symptoms during Therapy. Part IDigestion, 2004
- Do we need a new gastro‐oesophageal reflux disease questionnaire?Alimentary Pharmacology & Therapeutics, 2004
- GERD 2003 – A Consensus on the Way AheadDigestion, 2003
- Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitisAmerican Journal of Gastroenterology, 2002
- Esomeprazole 20 mg maintains symptom control in endoscopy‐negative gastro‐oesophageal reflux disease: a controlled trial of ‘on‐demand’ therapy for 6 monthsAlimentary Pharmacology & Therapeutics, 2001
- Pantoprazole 20 mg is effective for relief of symptoms and healing of lesions in mild reflux oesophagitisAlimentary Pharmacology & Therapeutics, 1998
- An evidence-based appraisal of reflux disease management — the Genval Workshop ReportGut, 1998